What is the difference between Eltrombopag and Hetrombopag?

Eltrombopag (Eltrombopag) and Hetrombopag (Hetrombopag) are both thrombopoietin receptor agonists (TPO-RA), which are mainly used to treat thrombocytopenia caused by immunity or liver disease. Although the two have similar mechanisms of action, both promoting platelet production by activating TPO receptors, they have certain differences in molecular structure, indications, and metabolism.

From a source point of view, eltrombopag is the first generation TPO receptor agonist developed by Novartis and is an imported original drug; while eltrombopag is a new generation TPO receptor agonist independently developed by China Hengrui Medicine. It is the first independently innovative small molecule TPO-RA drug in China. Eltrombopag has long been marketed in many European and American countries, while eltrombopag is mainly used in the Chinese market and is an important achievement of my country's local innovative drugs.

There are differences in indications between the two. Eltrombopag is widely used to treat chronic immune thrombocytopenia (ITP), severe aplastic anemia (SAA), and thrombocytopenia associated with chronic liver disease. The domestically approved indications of Hatrombopag are mainly focused on the treatment of chronic ITP. Although there are also clinical studies exploring its potential in other thrombocytopenic diseases, its current scope of application is relatively narrow.

From the perspective of pharmacokinetics, eltrombopag is metabolized more in the liver, so it is important to monitor liver function during use. At the same time, it is greatly affected by food, especially calcium-containing food, and it is usually required to be taken on an empty stomach. The bioavailability of Hetrombopag is relatively stable, less affected by diet, and is more convenient to take. In addition, Hetrombopag has shown good safety and tolerability in clinical trials, and is especially suitable for long-term treatment. Overall, eltrombopag and heltrombopag have their own advantages, and clinical selection should be comprehensively considered based on the patient's specific condition, drug availability, and economic factors.

Reference materials:https://go.drugbank.com/drugs/DB06210